Evidence of a tumour suppressor function for DLEC1 in human breast cancer
By: Al Sarakbi W, Reefy S, Jiang WG, Roberts T, Newbold RF, Mokbel K.

St. George's University of London, Tooting, London, UK.
Anticancer Res. 2010 Apr; 30(4):1079-82.

Abstract

Background

DLEC1 (deleted in lung and oesophageal cancer), located on 3p22.3, is a candidate tumour suppressor gene in lung, esophageal, and renal cancer. The aim of this study was determine whether the mRNA expression levels of DLEC1 were consistent with a tumour suppressive function.

Materials and Methods

A total of 153 samples were analysed. The levels of transcription of DLEC1 were determined using quantitative PCR and normalised against (CK19). Transcript levels within breast cancer specimens were compared to normal background tissues.

Results

Levels of transcription were higher in tumour samples compared to adjacent non cancerous tissue (ANCT) samples but this was not statistically significant (median 0.167 vs. 0.03; p=0.138). DLEC1 expression levels were significantly lower in samples from patients who developed metastasis, local recurrence, or died of breast cancer when compared to those who were disease free for >10 years (p=0.041).

Discussion

These findings are consistent with a possible tumour suppressor function of DLEC1 in breast cancer.

PMID: 20530412 [PubMed - in process] Source: National Library of Medicine.






* Albert Einstein College of Medicine has been
awarded Acceditation with Commendation by
the ACCME

Copyright 2025 InterMDnet | Privacy Policy | Disclaimer | System Requirements